Vantia Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vantia.com
Clinical Trials
14
Active:2
Completed:12
Trial Phases
2 Phases
Phase 1:8
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (66.7%)Phase 2
4 (33.3%)Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 432
- Registration Number
- NCT02637960
- Locations
- 🇺🇸
Vantia Investigative Center, Richmond, Virginia, United States
A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 43
- Registration Number
- NCT02537288
- Locations
- 🇩🇪
PAREXEL Early Phase Clinical Unit Berlin, Berlin, Germany
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 29
- Registration Number
- NCT02440841
- Locations
- 🇩🇪
PAREXEL Early Phase Clinical Unit Berlin, Berlin, Germany
Dose Range Finding Study of Fedovapagon in Men With Nocturia
Phase 2
Completed
- Conditions
- Nocturia
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 358
- Registration Number
- NCT01656239
- Locations
- 🇺🇸
Vantia Investigative Center, Middleton, Wisconsin, United States
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2011-08-02
- Lead Sponsor
- Vantia Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT01330927
- Locations
- 🇩🇪
Early Phase Clinical Unit, PAREXEL International GmbH, Berlin, Germany
- Prev
- 1
- 2
- 3
- Next
News
No news found